Retinal Vein Occlusion

Overview of branch retinal vein occlusion and central retinal vein occlusion.

What is a Retinal Vein Occlusion?

Arteries bring blood to the eye and veins bring blood back to the heart. While arteries have tough walls which usually become harder with age, veins have thin walls which remain pliant and soft throughout life. Because of the anatomy of the eye, the retinal veins are prone to occlusion. There are two main locations where retinal veins are occluded. One is at the crossing of a retinal arteriole and branch retinal vein. An occlusion at a crossing of a branch retinal arteriole and branch retinal vein causes a branch retinal vein occlusion. The second is at the main trunk of the retinal vein where it leaves the eye through the optic nerve. An occlusion at the main trunk of the retinal vein causes a central retinal vein occlusion. The picture shows a photo with dilated veins and retinal hemorrhages from a fresh central retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The retinal veins dilate and their are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen. Monthly examinations of pateints with CRVO for less than six months are very important. Some patients with CRVO and very bad circulation, develop a severe type of glaucoma. In this situation, the eye becomes red and painful and without treatment, total visual loss can occur rapidly. If an examining doctor sees early signs that this complication may occur, then laser treatment can sometimes protect the eye. Once the pressure rise occurs, surgery can be helpful.

Read more

Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Retinal Vein Occlusion

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article · Related *content* · Metrics ...

Aerie initiates trial of dexamethasone intravitreal implant for macular edema due to RVO  Healio

Aerie Pharmaceuticals has begun dosing in a phase 2 clinical trial of AR-1105, its dexamethasone intravitreal implant for patients with macular edema due to ...

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, ...

Serum oxidative biomarker in retina vein occlusion patients | Acta Ophthalmologica  MD Linx

Internal Medicine Article: Elevation of serum oxidative stress in patients with retina vein occlusions.

Global Retinal Vein Occlusion – Pipeline Insight, 2019  Redfield Report

Report Titled “Retinal Vein Occlusion – Pipeline Insight, 2019” provides product and API manufacturers' details across the globe along with the location.

Retinal Vein Occlusion Therapeutics Market to Reflect Steady Growth Rate by 2021 | Kentucky Breaking News Updates  Kentucky Journal 24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105  Zacks.com

Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  EurekAlert

Philadelphia, January 15, 2019 - A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology ...

Aerie Pharma launches mid-stage study of AR-1105  Seeking Alpha

Aerie Pharmaceuticals (AERI -0.9%) initiates a Phase 2 clinical trial evaluating AR-1105, its investigational dexamethasone intravitreal implant, in patients with ...

Retinal Vein Occlusion Treatment Market 2023 Trends, Top Manufactures, Market Dynamics, Industry Growth Analysis & Forecast  Flatland Today

Retinal Vein Occlusion Treatment Market report provides forecast of 2019-2023 which is a valuable source of understanding data for business strategies, growth ...

ADM-RAMP2 system could be therapeutic target for retinal vein occlusion  Drug Target Review

Researchers suggest that the retinoprotectivity of the ADM-RAMP2 system makes it an ideal therapeutic target for central retinal vein occlusion (CRVO).

Focus on Eyes: Vision loss and retinal vein occlusion  Florida Today

When a retinal vein is blocked, it can lead to severe loss of vision.

A Novel Therapeutic Target for Retinal Vein Occlusion  Technology Networks

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Recon: Apple Watch Identifies Irregular Heart Beat in Large Study  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Apple Watch detects irregular heart beat in large US ...

Retinal Vein Occlusion Therapeutics Market: Global Distributors, Traders and Dealers Marketing Channel Future Trend Prediction to 2025  Washington DC Herald

Global Retinal Vein Occlusion Therapeutics Market Insights, forecast to 2025 mainly highlights thoughtful facts and knowledge of Retinal Vein Occlusion ...

Macular Edema Treatment Market Archives  TechnoBleak

Macular Edema Treatment Market 2018 Opportunities, Competition from Opponents, Dynamics, Demand, Challenge and Risk and Forecast to 2026.

Retinal Vein Occlusion Therapeutics Market Opportunities, Growth, Drivers, Trends, Demand, Share and Analysis to 2025  Journal Worldwide

Retinal Vein Occlusion Therapeutics Market (2019-2025) research report is a professional and in-depth study on the current state focuses on the major drivers ...

Global Retinal Vein Occlusion Therapeutics Market Report Analysis by Market Competitors, Region, Product, Application and Forecast upto 2025  Rocket Herald News

Global Retinal Vein Occlusion Therapeutics Market 2025 report covers the market landscape and its growth prospects over the coming years. The report also ...

Bessemer Group Inc. Has $184,000 Holdings in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

Bessemer Group Inc. raised its stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 23.4% in the 4th quarter, according to the company in its ...

2019-2023 Global Retinal Vein Occlusion Treatment Market Key Players, Types, Industry Analysis, Manufacturers, Trends, Regions and Segments  Journal Worldwide

Retinal Vein Occlusion Treatment Market report gives SWOT analysis for new entrants and interested investors and viability of investment analysis for new ...

Global Retinal Vein Occlusion Therapeutics Market 2019-2026 | Manufacturers- Addmedica SAS, Annexin Pharmaceuticals AB, Formycon AG.  Market Reports

Scope of the Report: Retinal Vein Occlusion Therapeutics report mainly focuses on the Global market, especially in North America, Europe and Asia-Pacific, ...

Worldwide Retinal Vein Occlusion Pipeline Drugs Global Scenario and Growth Prospects Insight 2019  The Newsmates

“Retinal Vein Occlusion – Pipeline Insight, 2019” Report provides comprehensive insights into the ongoing therapeutic research and development. This Pipeline ...

Clearside's retinal vein occlusion therapy fails to meet phase 3 endpoint  Healio

Xipere, an investigational treatment for retinal vein occlusion, did not achieve its phase 3 clinical trial primary endpoint, Clearside Biomedical announced in a ...

Outlook advancing eye disease candidate ONS-5010  Seeking Alpha

Outlook Therapeutics (OTLK -4.5%) has filed an IND with the FDA seeking sign-off to start a U.S. Phase 3 clinical trial evaluating ONS-5010 for the treatment of ...

Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction  Zacks.com

Aerie (AERI) reports wider-than-expected Q4 loss. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

Retinal Vein Occlusion Therapeutics Market segmentation by Key Regions | Gross Margin, Profit, Analysis, Market Share, (Forecast 2019-2024)  The West Tribune

Retinal Vein Occlusion Therapeutics Market 2019-2024 starting from the basics to advanced Market intelligence which plays an essential part in managing.

Retinal Vein Occlusion Market Status 2019 Disease Type, Treatment Algorithm, Treatment Guidelines and Forecast 2028  Journal Worldwide

Retinal Vein Occlusion Market Insights, Epidemiology and Market Forecast studies the current scenario of market (with the base year being 2019), Key Cross ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 3.8% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. with ticker code (REGN) now have 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Global Retinal Vein Occlusion Therapeutics Market Size 2018-19 By Companies Graybug Vision, Addmedica, Acucela, Lupin  industrydailyobserver.com

Global Market Study Retinal Vein Occlusion Therapeutics Market Provide Forecast Report 2019–2026 presents an detailed analysis of the Retinal Vein ...

Clearside Biomedical Inc (CLSD) Given Consensus Recommendation of “Hold” by Brokerages  Fairfield Current

Shares of Clearside Biomedical Inc (NASDAQ:CLSD) have received an average rating of “Hold” from the eleven brokerages that are presently covering the firm, ...

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update  BioSpace

Conference Call and Webcast Today, February 25th, at 5:00 p.m. ET. DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), ...

OHR Pharmaceutical Inc. (OHRP)'s Financial Results Comparing With Evofem Biosciences Inc. (NASDAQ:EVFM)  Standard Recorder

OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Evofem Biosciences Inc. (NASDAQ:EVFM), both competing one another are Biotechnology companies. We will ...

Precise Analysis on Global Branch Retinal Vein Occlusion Clinical Trials Reviewed for H2, 2018  industrydailyobserver.com

The global market for Branch Retinal Vein Occlusion is likely to attain novel growth heights with fast transitioning end-user preferences. Burgeoning vegan ...

Global Retinal Vein Occlusion Therapeutics Market 2019: Growth, Size, Trends And Revenue 2025  Be Internet News

Global Retinal Vein Occlusion Therapeutics Market Report 2019 focuses on providing an adequate elaboration of the global Retinal Vein Occlusion ...

Retinal Vein Occlusion Therapeutics Market – Business Development, Size, Share, Analysis And Opportunities To 2025  Rochester Leader

Retinal Vein Occlusion Therapeutics Market Report covers the manufacturer's data, including shipment, price, gross profit, business distribution, industry ...

Laser-induced chorioretinal anastomosis can lessen CRVO treatment burden  Healio

Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according ...

Charming Shoppes Inc Stock in 2018 Q4 Driven by Institutional Investors | Thorold News  Thorold News

Charming Shoppes Inc (NASDAQ:CHRS) institutional sentiment increased to 1.29 in 2018 Q4. Its up 0.18, from 1.11 in 2018Q3. The ratio has improved, as 54 ...

Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update  Nasdaq

Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform-- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA.

Comparing of OHR Pharmaceutical Inc. (OHRP) and Amicus Therapeutics Inc. (NASDAQ:FOLD)  The Moveefy

This is a contrast between OHR Pharmaceutical Inc. (NASDAQ:OHRP) and Amicus Therapeutics Inc. (NASDAQ:FOLD) based on their dividends, analyst ...

Retinal Vein Occlusion Therapeutics Market 2019 – Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB, Chengdu Kanghong Pharmaceuticals Group Co Ltd  Market Reports

Recent study titled, “Retinal Vein Occlusion Therapeutics Market“ which covers detailed statistical analysis and enlightens market dynamics and trends that ...

CF Patients at Greater Risk for Occlusions in Retinal Vessels, Case Report Suggests  Cystic Fibrosis News Today

A case report suggests that cystic fibrosis patients have a higher risk of retinal vein occlusions as a complication of their pro-inflammatory status.

Reviewing Diffusion Pharmaceuticals Inc. (DFFN)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  The Moveefy

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) compete against each other in the Biotechnology sector.

Retinal Vein Occlusion Market Analysis by Major Companies, Size, Segmentation, Market Dynamics  Markets Pioneer

Retinal Vein Occlusion Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD Disclosure  Market Exclusive

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD Disclosure Item 7.01. Regulation FD Disclosure. Story continues below. On March 18 ...

Head to Head Analysis: Momenta Pharmaceuticals (MNTA) versus Halozyme Therapeutics (NASDAQ:HALO)  Fairfield Current

Halozyme Therapeutics (NASDAQ:HALO) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both medical companies, but which is the better business?

Global Retinal Vein Occlusion Therapeutics Market Insights 2019-2027: Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc  Industry News Blog

The global “Retinal Vein Occlusion Therapeutics market” research report portrays a deep analysis of the global Retinal Vein Occlusion Therapeutics market.

BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer  PRNewswire

BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that the National Comprehensive Cancer ...

Clearside Biomedical Inc. (CLSD) and ADMA Biologics Inc. (NASDAQ:ADMA) Comparing side by side  The FinExaminer

Both Clearside Biomedical Inc. (NASDAQ:CLSD) and ADMA Biologics Inc. (NASDAQ:ADMA) are each other's competitor in the Biotechnology industry. Thus the ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Retinal Vein Occlusion Therapeutics Market Research and Clinical Analysis 2019  Honest Businessman

The research report presents a comprehensive assessment of the Retinal Vein Occlusion Therapeutics market and contains thoughtful insights, facts, historical ...

Global Retinal Vein Occlusion Therapeutics Market Current Outlook with Noted Manufactures are Sanofi Aventis,Valeant Pharmaceuticals,Allergan  RISReport

The Global Retinal Vein Occlusion Therapeutics Market Report provides Insightful information to the clients enhancing their basic leadership capacity identified ...

Reviewing SELLAS Life Sciences Group Inc. (SLS)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  The Yomi Blog

Both SELLAS Life Sciences Group Inc. (NASDAQ:SLS) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are Biotechnology companies, competing one another.

Lido Advisors LLC Buys New Stake in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

Lido Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the 4th quarter, according to its most recent 13F ...

Global Retinal Vein Occlusion Treatment Market 2019-2023| Strong Pipeline and Recent Drug Approvals to Boost Demand | Technavio  Business Wire

The global retinal vein occlusion treatment market 2019-2023 is expected to post a CAGR of over 9% during the forecast period, according to Technavio.

Comparison of OHR Pharmaceutical Inc. (OHRP) and MacroGenics Inc. (NASDAQ:MGNX)  Thе Mоnіtоr

As Biotechnology businesses, OHR Pharmaceutical Inc. (NASDAQ:OHRP) and MacroGenics Inc. (NASDAQ:MGNX), are affected by compare. This especially ...

Retinal Vein Occlusion Therapeutics Market 2019 Precise Outlook – Acucela Inc, Addmedica SAS, Aerpio Therapeutics Inc, Annexin Pharmaceuticals AB  Market Reports

Global Retinal Vein Occlusion Therapeutics market is growing in various sectors at present years. The Retinal Vein Occlusion Therapeutics has covered rapid ...

Reviewing Coherus BioSciences Inc. (CHRS)'s and Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)'s results  Thе Mоnіtоr

We are contrasting Coherus BioSciences Inc. (NASDAQ:CHRS) and Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) on their dividends, analyst ...

Morphological Implications of Vascular Structures Not Visualized on Optical Coherence Tomography Angiography in Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:Advanced retinal imaging can improve understanding of retinal vein ...

Analyzing iCo Therapeutics (OTCMKTS:ICOTF) & Clearside Biomedical (CLSD)  Fairfield Current

iCo Therapeutics (OTCMKTS:ICOTF) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior stock?

CIExpert on Canada Life's individual CI upgrade | COVER  COVER

'Solid improvements that will increase claims paid,' says Alan Lakey.

Sun Hydraulics (SNHY) to pay $0.09 on Apr 20, 2019; Ohr Pharmaceutical Has 0.5 Sentiment  Lives Advice

Sun Hydraulics Corp (NASDAQ:SNHY) is expected to pay $0.09 on Apr 20, 2019. (NASDAQ:SNHY) shareholders before Apr 4, 2019 will receive the $0.09 ...

Effect of intravitreal ranibizumab on serous retinal detachment in bra | OPTH  Dove Medical Press

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion Emine Dogan,1 Ozkan Sever,2 Burcin Köklü Çakir,1 Erkan Celik1 ...

John G Ullman & Associates Upped By $304,000 Its Watts Water Tech Class A (WTS) Stake; Charming Shoppes (CHRS) Has 1.29 Sentiment  The Moveefy

John G Ullman & Associates Inc increased Watts Water Tech Inc Class A (WTS) stake by 4.4% reported in 2018Q4 SEC filing. John G Ullman & Associates Inc ...

Ozurdex for retinal vein occlusion available in China  Healio

Ozurdex is now available in China for the treatment of adult patients with macular edema secondary to retinal vein occlusion, Allergan announced in a press ...

Contrasting of Arbutus Biopharma Corporation (ABUS) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Thе Mоnіtоr

Arbutus Biopharma Corporation (NASDAQ:ABUS) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have been rivals in the Biotechnology for quite some ...

Regeneron Pharmaceuticals Inc. (REGN) and Kazia Therapeutics Limited (NASDAQ:KZIA) Contrasting side by side  Lives Advice

This is a contrast between Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Kazia Therapeutics Limited (NASDAQ:KZIA) based on their dividends, ...

Post-marketing surveillance study of the safety of dexamethasone intra | OPTH  Dove Medical Press

Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment ...

Financial Review: Advaxis (ADXS) vs. Clearside Biomedical (CLSD)  Fairfield Current

Clearside Biomedical (NASDAQ:CLSD) and Advaxis (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will compare ...

Medical conditions you need to tell the DVLA about before driving - or face £1,000 fine  Liverpool Echo

Here's the full list of medical conditions that could affect your driving.

Avastin as effective as Eylea for treating central retinal vein occlusion  National Institutes of Health

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion ...

Reviewing Regeneron Pharmaceuticals Inc. (REGN)'s and CytomX Therapeutics Inc. (NASDAQ:CTMX)'s results  Thе Mоnіtоr

We will be comparing the differences between Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and CytomX Therapeutics Inc. (NASDAQ:CTMX) as far as ...

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

What's Next for Ohr Pharmaceutical Inc (NASDAQ:OHRP) After Having More Shares Shorted? | Thorold News  Thorold News

Investors sentiment decreased to 0.5 in 2018 Q4. Its down 0.50, from 1 in 2018Q3. It dropped, as 4 investors sold OHR Pharmaceutical, Inc. shares while 8.

Analysts Anticipate Regeneron Pharmaceuticals Inc (REGN) to Post $5.47 Earnings Per Share  Fairfield Current

Equities analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report earnings per share (EPS) of $5.47 for the current fiscal quarter, Zacks ...

Clearside Biomedical (CLSD) Trading 9.4% Higher  Fairfield Current

Clearside Biomedical Inc (NASDAQ:CLSD) shares traded up 9.4% on Tuesday . The company traded as high as $1.47 and last traded at $1.40. 1321395 shares ...

Comparison of VistaGen Therapeutics Inc. (VTGN) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Standard Recorder

Both VistaGen Therapeutics Inc. (NASDAQ:VTGN) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are each other's competitor in the Biotechnology ...

Regeneron Pharmaceuticals Inc. (REGN) and RedHill Biopharma Ltd. (NASDAQ:RDHL) Contrasting side by side  The FinExaminer

Both Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and RedHill Biopharma Ltd. (NASDAQ:RDHL) are each other's competitor in the Biotechnology ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Allergan launches new surgical treatment for Glaucoma refractory to topical treatment in the United Arab Emirates  ZAWYA

XEN is a new minimally invasive option that provides an opportunity for refractory glaucoma patients The treatment system reduces intraocular pressure (IOP) in ...

Regulus Therapeutics Inc. (RGLS)'s Financial Results Comparing With Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)  Lives Advice

As Biotechnology businesses, Regulus Therapeutics Inc. (NASDAQ:RGLS) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), are affected by compare.

Ohr Pharmaceutical Inc (NASDAQ:OHRP) Stock Price Down as Sentiment Worsens | Thorold News  Thorold News

Ohr Pharmaceutical Inc (NASDAQ:OHRP) institutional sentiment decreased to 0.5 in Q4 2018. Its down -0.50, from 1 in 2018Q3. The ratio has dropped, as 6 ...

Head to Head Review: iCo Therapeutics (ICOTF) versus Clearside Biomedical (CLSD)  Fairfield Current

iCo Therapeutics (OTCMKTS:ICOTF) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better business?

Regeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of “Hold” from Brokerages  Fairfield Current

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has earned a consensus recommendation of “Hold” from the twenty-six analysts that are presently covering ...

Therapix Biosciences Ltd. (TRPX)'s Financial Results Comparing With OHR Pharmaceutical Inc. (NASDAQ:OHRP)  The FinHeadLines

Since Therapix Biosciences Ltd. (NASDAQ:TRPX) and OHR Pharmaceutical Inc. (NASDAQ:OHRP) are part of the Biotechnology industry, they are influenced by ...

Reviewing AmpliPhi Biosciences Corporation (APHB)'s and OHR Pharmaceutical Inc. (NASDAQ:OHRP)'s results  The Yomi Blog

This is therefore a contrasting of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in AmpliPhi.

Vascular Endothelial Market Analysis Outlook (2019-2025)| Alteogen Inc, CSL Ltd, Eli Lilly and Company, Formycon AG  Spot Herld

Los Angeles, United State, Mar 22, 2019– The report offers an exclusive research study of the global Vascular Endothelial market based on our honest, accurate ...

Regeneron Pharmaceuticals (REGN) Price Target Increased to $480.00 by Analysts at Oppenheimer  Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by research analysts at Oppenheimer from $440.00 to $480.00 in a research note ...

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $13.12 Million Holdings in Regeneron Pharmaceuticals Inc (REGN)  Fairfield Current

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 5.8% in the 4th quarter, ...

Vascular Endothelial Growth Factor B Market segments by Region, Manufactures, Types and Applications  The Warren Daily

Vascular Endothelial Growth Factor B Market provides top manufacturers, supply chain trends, technical inventions, important developments, and upcoming ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Comparison of Synthorx Inc. (THOR) and Coherus BioSciences Inc. (NASDAQ:CHRS)  Standard Recorder

Synthorx Inc. (NASDAQ:THOR) and Coherus BioSciences Inc. (NASDAQ:CHRS) compete against each other in the Biotechnology sector. We will contrast them ...

Europe's Luxturna approval tops November retina news  Healio

The European Commission's approval of Luxturna for inherited retinal disease was the most-read retina-related article on Healio.com/OSN in November.

Momenta Pharmaceuticals (MNTA) & Halozyme Therapeutics (HALO) Critical Contrast  Fairfield Current

Momenta Pharmaceuticals (NASDAQ:MNTA) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior business?

Institutional Investors Are Buying Charming Shoppes Inc (NASDAQ:CHRS) | Thorold News  Thorold News

Charming Shoppes Inc (NASDAQ:CHRS) institutional sentiment increased to 1.29 in 2018 Q4. Its up 0.18, from 1.11 in 2018Q3. The ratio has improved, as 54 ...

Reviewing Immune Design Corp. (IMDZ)'s and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)'s results  Lives Advice

Immune Design Corp. (NASDAQ:IMDZ) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have been rivals in the Biotechnology for quite some time.

Aflibercept Benefits Bevacizumab-Unresponsive Diabetic Retinopathy Patients  MD Magazine

A new analysis of an ongoing clinical study offers insights for treating retinal vein occlusion in poor responders to bevacizumab.

Surgical eye robot performs precision injection in patient with retinal vein occlusion  Medical Xpress

Eye surgeons at University Hospitals Leuven have been the first to use a surgical robot to operate on a patient with retinal vein occlusion. The robot uses a ...

Contrasting of Clearside Biomedical Inc. (CLSD) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC)  The FinHeadLines

Clearside Biomedical Inc. (NASDAQ:CLSD) and Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) compete against each other in the Biotechnology sector.

Clearside Biomedical, Inc. (NASDAQ:CLSD)  The Newburgh Press

Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using.

» Load more